Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 17/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603487 | 0.87 | SLC6A7 (0.58) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL3606615 | 0.77 | ALDH1A1 (0.59) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL3609735 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KDM4E | |
| SCHEMBL13316899 | 0.77 | SLC6A7 (0.53) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL3576489 | 0.73 | SLC6A7 (1.00) | SLC6A7ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL3604257 | 0.73 | HDAC6 (0.52) | — | |
| SCHEMBL13959037 | 0.71 | SLC6A7 (0.67) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL13149359 | 0.70 | SLC6A7 (0.92) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL220133 | 0.70 | L3MBTL1 (0.74) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL95079 | 0.70 | L3MBTL1 (0.74) | SLC6A7ALDH1A1TSHRL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | SLC6A7 1931/4885ALDH1A1 370/4885TSHR 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.